Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall
John D Cook

Biometrics

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Biometrics|September 2, 2004
Dose-finding based on efficacy-toxicity trade-offsPeter F Thall, John D Cook
Biometrics|March 14, 2002
Monitoring the rates of composite events with censored data in phase II clinical trialsYing Kuen Cheung, Peter F Thall
Biometrics|October 28, 2018
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase IIIAndrew G Chapple, Peter F Thall
Biometrics|July 6, 2019
An adaptive trial design to optimize dose-schedule regimes with delayed outcomesRuitao Lin, Peter F Thall, Ying Yuan
Biometrics|February 16, 2024
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparisonYong Zang, Peter F Thall, Ying Yuan
Biometrics|September 4, 2007
Determining the effective sample size of a parametric priorSatoshi Morita, Peter F Thall, Peter Müller
Biometrics|October 17, 2014
Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcomeRebecca Graziani, Michele Guindani, Peter F Thall
Biometrics|August 17, 2022
Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicityJuhee Lee, Peter F Thall, Pavlos Msaouel
Biometrics|July 14, 2005
Determining a maximum-tolerated schedule of a cytotoxic agentThomas M Braun, Zheng Yuan, Peter F Thall
Biometrics|October 3, 2024
ROMI: a randomized two-stage basket trial design to optimize doses for multiple indicationsShuqi Wang, Peter F Thall, Kentaro Takeda, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Biometrics|September 2, 2004
Dose-finding based on efficacy-toxicity trade-offsPeter F Thall, John D Cook
Biometrics|March 14, 2002
Monitoring the rates of composite events with censored data in phase II clinical trialsYing Kuen Cheung, Peter F Thall
Biometrics|October 28, 2018
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase IIIAndrew G Chapple, Peter F Thall
Biometrics|July 6, 2019
An adaptive trial design to optimize dose-schedule regimes with delayed outcomesRuitao Lin, Peter F Thall, Ying Yuan
Biometrics|February 16, 2024
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparisonYong Zang, Peter F Thall, Ying Yuan
Biometrics|September 4, 2007
Determining the effective sample size of a parametric priorSatoshi Morita, Peter F Thall, Peter Müller
Biometrics|October 17, 2014
Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcomeRebecca Graziani, Michele Guindani, Peter F Thall
Biometrics|August 17, 2022
Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicityJuhee Lee, Peter F Thall, Pavlos Msaouel
Biometrics|July 14, 2005
Determining a maximum-tolerated schedule of a cytotoxic agentThomas M Braun, Zheng Yuan, Peter F Thall
Biometrics|October 3, 2024
ROMI: a randomized two-stage basket trial design to optimize doses for multiple indicationsShuqi Wang, Peter F Thall, Kentaro Takeda, et al.
Pageof 3